Erratum to “Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism”

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

In the article titled “Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism” [1], the affiliation for I. Claro was labeled incorrectly. The correct affiliation of the author I. Claro is Instituto Português de Oncologia de Lisboa, Francisco Gentil (IPOLFG), 1099-023 Lisboa, Portugal.

Related collections

Most cited references 1

Record: found
Abstract: found
Article: found

Is Open Access

Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism

A. Santos, J. Vinagre, P. Soares … (2019)

Background The incidence of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) has been increasing in the last five decades, but there is no large-scale data regarding these tumours in Portugal. We conducted a cross-sectional, multicentric study in main Portuguese centers to evaluate the clinical, pathological, and therapeutic profile of GEP-NENs. Methods From November, 2012, to July, 2014, data from 293 patients diagnosed with GEP-NENs from 15 centers in Portugal was collected and registered in an online electronic platform. Results Median age at diagnosis was 56.5 (range: 15-87) years with a preponderance of females (54.6%). The most frequent primary sites were the pancreas (31.1%), jejunum-ileum (24.2%), stomach (13.7%), and rectum (8.5%). Data regarding hormonal status was not available in most patients (82.3%). Stratified by the tumour grade (WHO 2010 classification), we observed 64.0% of NET G1, 24.7% of NET G2, and 11.3% of NEC. Poorly differentiated tumours occurred mainly in older patients (p = 0.017), were larger (p < 0.001), and presented more vascular (p = 0.004) and lymphatic (p = 0.001) invasion. At the time of diagnosis, 44.4% of GEP-NENs presented metastatic disease. Surgery (79.6%) and somatostatin analogues (30.7%) were the most frequently used therapies of GEP-NENs with reported grading. Conclusion In general, Portuguese patients with GEP-NENs presented similar characteristics to other populations described in the literature. This cross-sectional study represents the first step to establish a national database of GEP-NENs that may aid in understanding the clinical and epidemiological features of these tumours in Portugal.

0 comments Cited 2 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

A. P. Santos:

ORCID: https://orcid.org/0000-0002-8896-305X

Journal

Journal ID (nlm-ta): Int J Endocrinol

Journal ID (iso-abbrev): Int J Endocrinol

Journal ID (publisher-id): IJE

Title: International Journal of Endocrinology

Publisher: Hindawi

ISSN (Print): 1687-8337

ISSN (Electronic): 1687-8345

Publication date Collection: 2020

Publication date (Electronic): 18 June 2020

Publication date PMC-release: 18 June 2020

Volume: 2020

Electronic Location Identifier: 9184324

Affiliations

¹Instituto Português de Oncologia do Porto, Francisco Gentil (IPOPFG), 4200-072 Porto, Portugal

²Instituto de Investigação e Inovação em Saúde (i3S), 4200-135 Porto, Portugal

³Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), 4200-465 Porto, Portugal

⁴Faculdade de Medicina da Universidade do Porto (FMUP), 4200-319 Porto, Portugal

⁵Centro Hospitalar de São João (CHSJ), 4200-319 Porto, Portugal

⁶Instituto Português de Oncologia de Lisboa, Francisco Gentil (IPOLFG), 1099-023 Lisboa, Portugal

⁷Centro Hospitalar e Universitário de Coimbra (CHUC), 3000-075 Coimbra, Portugal

⁸Centro Hospitalar Lisboa Norte, EPE (CHLN), 1649-035 Lisboa, Portugal

⁹Centro Académico de Medicina de Lisboa (CAML), 1649-035 Lisboa, Portugal

¹⁰Hospital da Luz, 1500-650 Lisboa, Portugal

¹¹Hospital Garcia de Orta, EPE, 2801-951 Almada, Portugal

¹²Unidade Local de Saúde de Matosinhos, 4464-513 Senhora da Hora, Portugal

¹³Instituto Português de Oncologia de Coimbra, Francisco Gentil (IPOCFG), 3000-075 Coimbra, Portugal

¹⁴Centro Hospitalar do Porto-Hospital Santo António, 4099-001 Porto, Portugal

¹⁵Centro Hospitalar Gaia/Espinho (CHGE), 4434-502 Vila Nova de Gaia, Portugal

¹⁶Centro Hospitalar do Baixo Vouga (CHBV), 3810-501 Aveiro, Portugal

¹⁷Centro Hospitalar de Lisboa Ocidental (CHLO), 1349-019 Lisboa, Portugal

¹⁸Portuguese Society of Endocrinology, Diabetes and Metabolism, Rua Fernando Vicente Mendes, 1B1600-892 Lisboa, Portugal

Author information

A. P. Santos https://orcid.org/0000-0002-8896-305X

J. Vinagre https://orcid.org/0000-0002-0871-1427

P. Soares https://orcid.org/0000-0001-9607-6998

J. M. Lopes https://orcid.org/0000-0001-8597-3474

M. J. Bugalho https://orcid.org/0000-0003-0357-7350

Article

DOI: 10.1155/2020/9184324

PMC ID: 7320291

SO-VID: d1ae217b-2d7f-4cb2-947b-4d929d92ea65

License:

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

History

Date received : 21 April 2020

Date accepted : 21 April 2020

Comments

Comment on this article

scite_

Most referenced authors 18

See all reference authors

- Version 1